Online inquiry

IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3141MR)

This product GTTS-WQ3141MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets C3&C4 gene. The antibody can be applied in Cardiopulmonary bypass (CPB) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000064.4; NM_001002029.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 718; 721
UniProt ID P01024; P0C0L4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3141MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13217MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ8546MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Hu5A8
GTTS-WQ10455MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ8782MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ15069MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ6188MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ11780MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ12729MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-305B83
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW